AstraZeneca will launch a new online platform to make Airsupra, as well as Farxiga and Flumist, available for home delivery ...

Evkeeza is now approved for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients as young as 1 year ...

Recent analysis reveals Medicaid's impact on mortality, highlighting the need for diverse research methods to inform policy ...

Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more ...

A new targeted therapy has shown promise for a difficult-to-treat subset of lung cancer. In a multinational phase 2 trial, the oral drug sunvozertinib produced durable tumor responses in patients with ...

The expiration of ACA tax credits threatens $32 billion in healthcare revenue, risking coverage for millions and increasing ...

Today’s announcement builds on a previous announcement of more than 40% off the Eliquis list price, a direct-to-consumer ...

The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) ...

MedImpact launches a performance-driven PMPM pricing model, enhancing cost predictability and accountability for health plans amid rising pharmacy expenses.

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

Panelists discuss how bimekizumab demonstrated significant improvements in pain scores (from baseline levels around 60/100) and fatigue measures, with meaningful percentages of patients achieving ...